Kostas Zervas

Author PubWeight™ 7.49‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma. Br J Haematol 2006 1.56
2 Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008 1.01
3 Bortezomib is an effective agent for MDS/MPD syndrome with 5q- anomaly and thrombocytosis. Leuk Res 2006 0.92
4 Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group. Am J Hematol 2013 0.91
5 Evaluation of five staging systems in 470 patients with multiple myeloma. Haematologica 2006 0.80
6 Inhibition of factor VIIa generation and prothrombin activation by treatment with enoxaparin in patients with unstable angina. Br J Haematol 2003 0.78
7 On the mechanism of action of recombinant activated factor VII administered to patients with severe thrombocytopenia and life-threatening haemorrhage: focus on prothrombin activation. Br J Haematol 2002 0.77
8 Multiple myeloma staging based on the combination of beta-2-microglobulin and albumin: the role of albumin in the model. Hematology 2007 0.76
9 Evaluation of hypochromic erythrocytes in combination with sTfR-F index for predicting response to r-HuEPO in anemic patients with multiple myeloma. Lab Hematol 2006 0.75